vTv Therapeutics, Inc. - VTVT Quarterly EPS earnings growth

vTv Therapeutics Inc. - graphic logo of issuer VTVT

Quarterly earnings per share (EPS) growth for vTv Therapeutics Inc. (VTVT) demonstrates the impact of global cooperation and logistical barriers on component supply chains. The current status is 13.40, highlighting margin volatility. Growth potential is based on the development of TTP399 for diabetics, and the prospects for resuming clinical trials with investor support create opportunities for a market breakthrough, despite past delays.

vTv Therapeutics (VTVT) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/18/2026

Financial and market metric breakdowns for vtvtherapeutics.com (VTVT)

- share price and consensus valuation forecast:
Analysis of all company metrics:vTv Therapeutics Inc.
Manufactured product of vTv Therapeutics Inc.

Professional capital evaluates vTv Therapeutics Inc. (VTVT) through net earnings per share dynamics to understand the efficiency of developing drugs for diabetes and Alzheimer's disease. Comparing quarterly EPS allows for the daily tracking of profit growth rates between reports, identifying seasonal yield fluctuations and determining the fundamental stability of this high-tech pharmaceutical asset.

Competitors of vTv Therapeutics Inc. (VTVT)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS